SNM: GE highlights molecular imaging portfolio

GE Healthcare showcased its platform of imaging agents and imaging systems, including a new PET/CT scanner, at the 2009 SNM meeting this week in Toronto.

The company unveiled the Discovery PET/CT 690, a system with specialized detector configuration designed for sensitivity, throughput and efficiency in clinical techniques, drug discovery and motion management, according to GE.

The new system includes MotionFree imaging technology integrated with VUE Point FX, a high-definition reconstruction technique incorporating the element of time, GE said.

The company also showcased ith its Alcyone Technology, a nuclear cardiology platform combining cadmium zinc telluride (CZT) detectors, focused pin-hole collimation, 3D reconstruction, and stationary data acquisition, to improve workflow, dose management and overall image quality.

The Alcyone platform is available on SPECT (Discovery NM 530c) and SPECT/CT (Discovery NM/CT 570c) systems.

At the conference, GE launched the Xeleris Suite--a collection of nuclear medicine clinical applications integrated with the functionality of Centricity PACS RA1000 workstation, which allows users to operate from a single radiology department worklist, creating one shared worklist for the entire nuclear medicine department.

The company also highlighted its line of radiopharmaceuticals, including AdreView (Iobenguane I 123) and Myoview (99mTc-Tetrofosmin), as well as its Tracercenter-GMP tracer production center.



Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.